Evidence map›Paper›PMID 24821784›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2014

Circulating proteolytic signatures of chemotherapy-induced cell death in humans discovered by N-terminal labeling.

Arun P Wiita, Gerald W Hsu, Chuanyi M Lu, Jonathan H Esensten, James A Wells

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Discovery of a caspase cleavage motif antibody reveals insights into noncanonical inflammasome function.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Arun P WiitaDepartments of Laboratory Medicine,Pharmaceutical Chemistry, and.
Gerald W HsuDivision of Hematology and Medical Oncology and.
Chuanyi M LuDepartments of Laboratory Medicine,Laboratory Medicine Service, Veterans Affairs Medical Center, San Francisco, CA 94121.
Jonathan H EsenstenDepartments of Laboratory Medicine.
James A WellsPharmaceutical Chemistry, andCellular and Molecular Pharmacology, University of California, San Francisco, CA 94158; and jim.wells@ucsf.edu.

Funding

Bio-Organic Biomedical Mass Spectromy ResourceP41GM103481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BURLINGAME, ALMA L · 2012 to 2015
$6.4M
Global Analysis of Proteolysis in ApoptosisR01GM081051 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WELLS, JAMES A · 2007 to 2015
$2.8M
Approaches to discover and quantify apoptotic biomarkers for cancer treatmentR01CA154802 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WELLS, JAMES A · 2011 to 2014
$1.3M
Howard Hughes Medical InstituteNCI NIH HHS CA154802NCI NIH HHS R01 CA154802NIGMS NIH HHS 8P41GM103481NIGMS NIH HHS P41 GM103481NIGMS NIH HHS R01 GM081051
6 · The paper itself

Abstract

It is known that many chemotherapeutics induce cellular apoptosis over hours to days. During apoptosis, numerous cellular proteases are activated, most canonically the caspases. We speculated that detection of proteolytic fragments released from apoptotic cells into the peripheral blood may serve as a unique indicator of chemotherapy-induced cell death. Here we used an enzymatic labeling process to positively enrich free peptide α-amines in the plasma of hematologic malignancy patients soon after beginning treatment. This N-terminomic approach largely avoids interference by high-abundance proteins that complicate traditional plasma proteomic analyses. Significantly, by mass spectrometry methods, we found strong biological signatures of apoptosis directly in the postchemotherapy plasma, including numerous caspase-cleaved peptides as well as relevant peptides from apoptotic and cell-stress proteins second mitochondria-derived activator of caspases, HtrA serine peptidase 2, and activating transcription factor 6. We also treated hematologic cancer cell lines with clinically relevant chemotherapeutics and monitored proteolytic fragments released into the media. Remarkably, many of these peptides coincided with those found in patient samples. Overall, we identified 153 proteolytic peptides in postchemotherapy patient plasma as potential indicators of cellular apoptosis. Through targeted quantitative proteomics, we verified that many of these peptides were indeed increased post- vs. prechemotherapy in additional patients. Our findings reveal that numerous proteolytic fragments are released from dying tumor cells. Monitoring posttreatment proteolysis may lead to a novel class of inexpensive, rapid biomarkers of cell death.

Indexed as

Activating Transcription Factor 6Antineoplastic Combined Chemotherapy ProtocolsApoptosisBiomarkers, TumorEnzyme-Linked Immunosorbent AssayHigh-Temperature Requirement A Serine Peptidase 2HumansMass SpectrometryMitochondrial ProteinsPeptide FragmentsProteolysisSerine EndopeptidasesActivating Transcription Factor 6Biomarkers, TumorHigh-Temperature Requirement A Serine Peptidase 2HTRA2 protein, humanMitochondrial ProteinsPeptide FragmentsSerine Endopeptidases

Identifiers

PMID24821784
PMCPMC4040605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.